These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

215 related articles for article (PubMed ID: 36597887)

  • 21. Metabolomic Differences in Connective Tissue Disease-Associated Versus Idiopathic Pulmonary Arterial Hypertension in the PVDOMICS Cohort.
    Simpson CE; Hemnes AR; Griffiths M; Grunig G; Tang WHW; Garcia JGN; Barnard J; Comhair SA; Damico RL; Mathai SC; Hassoun PM;
    Arthritis Rheumatol; 2023 Dec; 75(12):2240-2251. PubMed ID: 37335853
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Identification of Cardiac MRI and Bio-Marker Thresholds for One-Year Survival in Pre-Capillary Pulmonary Hypertension: Prospective Study.
    Padervinskiene L; Hoppenot D; Krivickiene A; Gumauskiene B; Nedzelskiene I; Simkus P; Miliauskas S; Jankauskas A; Basevicius A; Ereminiene E
    Medicina (Kaunas); 2020 Apr; 56(4):. PubMed ID: 32283599
    [No Abstract]   [Full Text] [Related]  

  • 23. Right Heart End-Systolic Remodeling Index Strongly Predicts Outcomes in Pulmonary Arterial Hypertension: Comparison With Validated Models.
    Amsallem M; Sweatt AJ; Aymami MC; Kuznetsova T; Selej M; Lu H; Mercier O; Fadel E; Schnittger I; McConnell MV; Rabinovitch M; Zamanian RT; Haddad F
    Circ Cardiovasc Imaging; 2017 Jun; 10(6):. PubMed ID: 28592589
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Baseline NT-proBNP correlates with change in 6-minute walk distance in patients with pulmonary arterial hypertension in the pivotal inhaled treprostinil study TRIUMPH-1.
    Frantz RP; McDevitt S; Walker S
    J Heart Lung Transplant; 2012 Aug; 31(8):811-6. PubMed ID: 22759797
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The Consistent Effectiveness and Safety of Macitentan Therapies Across Idiopathic and Congenital Heart Disease-Associated PulmonaryArterial Hypertension: A Single-Center Experience.
    Kaymaz C; Tanyeri S; Tokgöz HC; Akbal ÖY; Karagöz A; Keskin B; Kültürsay B; Hakgör A; Külahçıoğlu Ş; Bayram Z; Efe SÇ; Tanboğa İH; Doğan C; Akbulut M; Özdemir N
    Anatol J Cardiol; 2022 Oct; 26(10):778-787. PubMed ID: 36196862
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The association of N-terminal pro-brain-type natriuretic peptide with hemodynamics and functional capacity in therapy-naive precapillary pulmonary hypertension: results from a cohort study.
    Berghaus TM; Kutsch J; Faul C; von Scheidt W; Schwaiblmair M
    BMC Pulm Med; 2017 Dec; 17(1):167. PubMed ID: 29202745
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Upfront combination therapy reduces right ventricular volumes in pulmonary arterial hypertension.
    van de Veerdonk MC; Huis In T Veld AE; Marcus JT; Westerhof N; Heymans MW; Bogaard HJ; Vonk-Noordegraaf A
    Eur Respir J; 2017 Jun; 49(6):. PubMed ID: 28663315
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Utility of right ventricular Tei-index for assessing disease severity and determining response to treatment in patients with pulmonary arterial hypertension.
    Ogihara Y; Yamada N; Dohi K; Matsuda A; Tsuji A; Ota S; Ishikura K; Nakamura M; Ito M
    J Cardiol; 2014 Feb; 63(2):149-53. PubMed ID: 24012334
    [TBL] [Abstract][Full Text] [Related]  

  • 29. NT-proBNP can be used to detect right ventricular systolic dysfunction in pulmonary hypertension.
    Blyth KG; Groenning BA; Mark PB; Martin TN; Foster JE; Steedman T; Morton JJ; Dargie HJ; Peacock AJ
    Eur Respir J; 2007 Apr; 29(4):737-44. PubMed ID: 17135228
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The Role of Noninvasive Endpoints in Predicting Long-Term Outcomes in Pulmonary Arterial Hypertension.
    Wronski SL; Mordin M; Kelley K; Anguiano RH; Classi P; Shen E; Manaker S
    Lung; 2020 Feb; 198(1):65-86. PubMed ID: 31722043
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Mechanistic Phase II Clinical Trial of Metformin in Pulmonary Arterial Hypertension.
    Brittain EL; Niswender K; Agrawal V; Chen X; Fan R; Pugh ME; Rice TW; Robbins IM; Song H; Thompson C; Ye F; Yu C; Zhu H; West J; Newman JH; Hemnes AR
    J Am Heart Assoc; 2020 Nov; 9(22):e018349. PubMed ID: 33167773
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Right Ventricular and Right Atrial Function Are Less Compromised in Pulmonary Hypertension Secondary to Heart Failure With Preserved Ejection Fraction: A Comparison With Pulmonary Arterial Hypertension With Similar Pressure Overload.
    van Wezenbeek J; Kianzad A; van de Bovenkamp A; Wessels J; Mouratoglou SA; Braams NJ; Jansen SMA; Meulblok E; Meijboom LJ; Marcus JT; Vonk Noordegraaf A; José Goumans M; Jan Bogaard H; Handoko ML; de Man FS
    Circ Heart Fail; 2022 Feb; 15(2):e008726. PubMed ID: 34937392
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Circulating markers of inflammation and angiogenesis and clinical outcomes across subtypes of pulmonary arterial hypertension.
    Hirsch K; Nolley S; Ralph DD; Zheng Y; Altemeier WA; Rhodes CJ; Morrell NW; Wilkins MR; Leary PJ; Rayner SG
    J Heart Lung Transplant; 2023 Feb; 42(2):173-182. PubMed ID: 36470771
    [TBL] [Abstract][Full Text] [Related]  

  • 34. SERAPHIN haemodynamic substudy: the effect of the dual endothelin receptor antagonist macitentan on haemodynamic parameters and NT-proBNP levels and their association with disease progression in patients with pulmonary arterial hypertension.
    Galiè N; Jansa P; Pulido T; Channick RN; Delcroix M; Ghofrani HA; Le Brun FO; Mehta S; Perchenet L; Rubin LJ; Sastry BKS; Simonneau G; Sitbon O; Souza R; Torbicki A
    Eur Heart J; 2017 Apr; 38(15):1147-1155. PubMed ID: 28329315
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The association of the N-terminal pro-brain-type natriuretic peptide response to exercise with disease severity in therapy-naive pulmonary arterial hypertension: a cohort study.
    Kutsch J; Faul C; von Scheidt W; Schwaiblmair M; Berghaus TM
    Respir Res; 2018 Jan; 19(1):8. PubMed ID: 29334941
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Time-Velocity Integral of Left Ventricular Outflow Tract Predicts Worse Long-Term Survival in Pulmonary Arterial Hypertension.
    Liu QQ; Yang J; Lu D; Xu XQ; Jiang X; Wang H; Li JY; Guo F; Zhu YL; Zhao QH
    JACC Asia; 2022 Jun; 2(3):235-243. PubMed ID: 36338398
    [TBL] [Abstract][Full Text] [Related]  

  • 37. High N-terminal pro-brain natriuretic peptide levels and low diffusing capacity for carbon monoxide as independent predictors of the occurrence of precapillary pulmonary arterial hypertension in patients with systemic sclerosis.
    Allanore Y; Borderie D; Avouac J; Zerkak D; Meune C; Hachulla E; Mouthon L; Guillevin L; Meyer O; Ekindjian OG; Weber S; Kahan A
    Arthritis Rheum; 2008 Jan; 58(1):284-91. PubMed ID: 18163505
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Assessment of right ventricular function in patients with pulmonary arterial hypertension-congenital heart disease and repaired and unrepaired defects: Correlation among speckle tracking, conventional echocardiography, and clinical parameters.
    Kemal HS; Kayıkçıoğlu M; Nalbantgil S; Can LH; Moğulkoç N; Kültürsay H
    Anatol J Cardiol; 2020 Apr; 23(5):277-287. PubMed ID: 32352408
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Simvastatin as a treatment for pulmonary hypertension trial.
    Wilkins MR; Ali O; Bradlow W; Wharton J; Taegtmeyer A; Rhodes CJ; Ghofrani HA; Howard L; Nihoyannopoulos P; Mohiaddin RH; Gibbs JS;
    Am J Respir Crit Care Med; 2010 May; 181(10):1106-13. PubMed ID: 20460548
    [TBL] [Abstract][Full Text] [Related]  

  • 40.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.